Diagnostics
RMDM Diagnostics is the next stage in delivering the pioneering blood test and imaging screening program for early cancer detection.
Working with Dr Johannes Coy, the mastermind behind the development of EDIM, we have built upon robust foundations to deliver an affordable and non-invasive blood test and screening program that is transforming the way we view and diagnose cancer.
PanTum Detect: A blood test for the early detection of tumour types
PanTum Detect is a pioneering early screening test that can filter asymptomatic healthy individuals by screening for the presence of silently growing benign, premalignant or malignant tumours.
Safe, proven and reliable, PanTum Detect is made possible by the innovative EDIM (Epitope Detection in Macrophages) technology Dr Coy and his team developed.
EDIM draws upon the natural mechanism of the immune system to detect universal biomarkers Apo10 and TKTL1 – one of which is detectable in all phases of tumour genesis (Apo10) . These two genes have been pivotal in developing EDIM technology. Apo10 presents with the earliest signs of tumour development, whilst TKTL1 manifests at the early signs of tumour malignancy and metastasis. The TKTL1 biomarker was discovered and patented by Dr Coy.
Early Cancer Diagnosis
With over 200 different types of cancer, recent research data published by Cancer Research UK shows that 1 in 2 people in the UK will get cancer in their lifetime.
PanTum Detect can provide early cancer diagnosis, giving people enough time to make positive and impactful lifestyle changes.
Detecting tumours before they evolve and spread into life-threatening cancers gives time for targeted medical intervention at an early stage, increasing survival rates and preventing relapses.
Explore some of the most commonly asked questions.
Screening Program: PanTum Detect + PET/CT
High Specificity | High Sensitivity | Non-invasive | Quick and Simple Process | Affordable
PanTum Detect provides a very high test accuracy (sensitivity of 82.3% and a specificity of 99.2%), meaning that missed tumours and false positives are highly unlikely.
In addition, it is a quick and simple, non-invasive process that is affordable, allowing for regular, annual testing.
The screening program combines PanTum Detect with an MRI, PET/CT scan and physician consultation, which allows for safe cancer screening by filtering out non-cancer suspicious patients.
Most potentially dangerous tumours are able to be detected at a very early stage using imaging methods (such as MRI, PET/CT, etc.).
However, due to the high costs and radiation exposure (e.g. PET/CT), these procedures are not suitable for use without tumour-suspicion.
This convenient blood test combined with imaging empowers us all to detect cancer early, increasing the success rate of cancer treatment.
With this technology, we can replace fear with a simple step to healthier lives.
Innovative Technology | Diverse Areas of Application
With further studies and tests planned, our technology will have a wide range of clinical applications.
In-depth research is already underway into the therapeutic benefits of our work in areas as varied as Alzheimer’s, dementia and diabetes.
To read the research that underpins EDIM technology and the PanTum Detect test, please visit our Research & Publications section or contact us.
RMDM Diagnostic Locations
London
UK Headquaters
1 Knightsbridge Green,
London,
SW1X 7QA.
Lebanon Doctors Center Lab
Cairo street – Near AUBMC – Hamra – Beirut, Lebanon.
Phone: +916-1- 344 311
Fax: +961-1-740 311
Email: info@dcrl.co
Website: www.dcrl.co
Saudi Arabia
Coming Soon
Dubai
UAE Doctors Center Polyclinic
7B – Al Shasha St – Umm Suqeim – Umm Suqeim 1 – Dubai – United Arab Emirates.
Phone: +971 4 507 4600
Email: info@doctorscenterdxb.com,
Website: https://doctorscenterdxb.com
RMDM Diagnostic Territories
London
UK Headquaters
1 Knightsbridge Green,
London,
SW1X 7QA.
Lebanon Doctors Center Lab
Cairo street – Near AUBMC – Hamra – Beirut, Lebanon.
Phone: +916-1-344-311
Fax: +961-1-740 311
Email: info@dcrl.co
Website: www.dcrl.co
Saudi Arabia
Coming Soon
Dubai
UAE Doctors Center Polyclinic
7B – Al Shasha St – Umm Suqeim – Umm Suqeim 1 – Dubai – United Arab Emirates.
Phone: +971 4 507 4600
Email: info@doctorscenterdxb.com
Website: https://doctorscenterdxb.com
Other Resources You Might Find Useful
New Research Links Sugar-Sweetened Beverages to Oral Cavity Cancer Risk in Women
A recent study published in JAMA Otolaryngology has uncovered a concerning link between the consumption of sugar-sweetened beverages (SSBs) and an increased risk of oral cavity cancer in women, including both smokers and non-smokers. The findings show that women who regularly consumed sugary drinks were found to have a significantly…
Advancing Prostate Cancer Detection: The Role of AI and Blood-Based Screening
The AI-powered prostate cancer test developed by EDX Medical Group represents a major advancement in early detection. By analysing over 100 biological markers in blood and urine samples, it offers a more accurate assessment of prostate cancer risk than traditional methods like PSA testing, highlighting the critical role of early…
NHS Backlogs, Less Rhetoric and More Solutions by Dr. Letizia Gulino, Head of Science and Technology RMDM
We are witnessing a crucial moment for the NHS as it promises to reduce waiting lists and deliver timely care. This commitment resonates with patients and healthcare professionals. However, while the intentions behind these proposals are laudable, critical questions remain regarding their feasibility, workforce capacity, and long-term sustainability by the…
Reforming Prostate Cancer Testing: Chris Hoy’s Urgent Appeal for Change
Olympic cyclist Sir Chris Hoy is advocating for improved prostate cancer tests for younger men following his terminal diagnosis in September 2023. His recent interview with the BBC reveals the limitations of the NHS’s current protocol for prostate cancer testing.
Government and Tech Innovators Unite to Advance Cancer Detection: The Potential of Pantum Detect
In a recent press release, the UK government outlined an initiative to boost tech deals aimed at further innovating cancer diagnosis in the country. This plan follows the Darzi review, which highlighted the critical state of the NHS, particularly the urgent need to improve cancer survival rates.
Darzi Report Findings: The Urgent Need for Innovative Technology in NHS Cancer Care
In the House of Commons, Health Secretary Wes Streeting introduced a "national mission" to tackle key health challenges. Presenting the Darzi report, commissioned by the Labour government, he outlined the NHS's ongoing struggles in the post-pandemic era, including missed targets in cancer care, A&E services, and hospital treatment.
The UK’s Approach to Multi-Cancer Detection Tests
Last month, the UK National Screening Committee (UK NSC) shared their updated view on Multi-Cancer Detection (MCD) tests. They highlighted the potential and the immediate need for a multi-cancer detection solution in the UK. They are working to outline a roadmap for finding this solution. At RMDM, we are at…
Why Multi-Cancer Early Detection Tests are the Future
Historically, early detection has focused on routine screenings for only a handful of cancers, such as breast, colorectal, cervical, lung, and prostate cancers. However, these screenings are not always effective. Many cancers are still detected at later stages when treatment is less effective. This challenge has motivated scientists to develop…
The Problem with the Cancer Waiting Time Crisis
Last month the BBC revealed that “cancer waiting times for 2023 in England were the worst on record”. Only 64.1% of patients started treatment within 62 days of a cancer suspicion, meaning nearly 100,000 waited longer than they should for life-saving care. These numbers are not just another statistic, they…
The Effect of TKTL1 in Breast Cancer: A Biomarker for Early Detection
Breast cancer is the second leading cause of cancer-related deaths in women. Thanks to pioneering research and diagnostic tests, we are discovering solutions to detect breast cancer early on. The TKTL1 gene, in particular, represents an incredible leap in our understanding of metabolism and cancer cell growth. In a new…